New biomarker analyses from the phase 3 KEYNOTE-522 trial provide insights into the biological factors that may influence response to pembrolizumab plus chemotherapy in early-stage triple-negative ...
TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...
Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback